Evidence map›Paper›PMID 39462863›Full record

ArticleProteins2025

PIM-1L Kinase Binds to and Inactivates SRPK1: A Biochemical and Molecular Dynamics Study.

Nastazia Lesgidou, Anastasia Koukiali, Eleni Nikolakaki, Thomas Giannakouros, Metaxia Vlassi

Abstract read
In one paragraph

Article in Proteins, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Nastazia LesgidouInstitute of Biosciences and Applications, National Center for Scientific Research "Demokritos", Athens, Greece.
Anastasia KoukialiLaboratory of Biochemistry, Department of Chemistry, Aristotle University, Thessaloniki, Greece.
Eleni NikolakakiLaboratory of Biochemistry, Department of Chemistry, Aristotle University, Thessaloniki, Greece.
Thomas GiannakourosLaboratory of Biochemistry, Department of Chemistry, Aristotle University, Thessaloniki, Greece.
Metaxia VlassiInstitute of Biosciences and Applications, National Center for Scientific Research "Demokritos", Athens, Greece.ORCID 0000-0003-0931-2660

Funding

Greece and the European Union (NSRF 2014-2020) MIS5002550
6 · The paper itself

Abstract

SR/RS dipeptide repeats vary in both length and position, and are phosphorylated by SR protein kinases (SRPKs). PIM-1L, the long isoform of PIM-1 kinase, the splicing of which has been implicated in acute myeloid leukemia, contains a domain that consists largely of repeating SR/RS and SH/HS dipeptides (SR/SH-rich). In order to extend our knowledge on the specificity and cellular functions of SRPK1, here we investigate whether PIM-1L could act as substrate of SRPK1 by a combination of biochemical and computational approaches. Our biochemical data showed that the SR/SH-rich domain of PIM-1L was able to associate with SRPK1, yet it could not act as a substrate but, instead, inactivated the kinase. In line with our biochemical data, molecular modeling followed by a microsecond-scale all-atom molecular dynamics (MD) simulation suggests that the SR/SH-rich domain acts as a pseudo-docking peptide that binds to the same acidic docking-groove used in other SRPK1 interactions and induces inactive SRPK1 conformations. Comparative community network analysis of the MD trajectories, unraveled the dynamic architecture of apo SRPK1 and notable alterations of allosteric communications upon PIM-1L peptide binding. This analysis also allowed us to identify key SRPK1 residues, including unique ones, with a pivotal role in mediating allosteric signal propagation within the kinase core. Interestingly, most of the identified amino acids correspond to cancer-associated amino acid changes, validating our results. In total, this work provides insights not only on the details of SRPK1 inhibition by the PIM-1L SR/SH-domain, but also contributes to an in-depth understanding of SRPK1 regulation.

Indexed as

Protein Serine-Threonine KinasesProto-Oncogene Proteins c-pim-1Binding SitesHumansMolecular Docking SimulationMolecular Dynamics SimulationPhosphorylationProtein BindingProtein DomainsSubstrate SpecificityPIM1 protein, humanProtein Serine-Threonine KinasesProto-Oncogene Proteins c-pim-1SRPK1 protein, humanallosteric communicationscancer mutationscommunity map analysismolecular dynamics simulationsPIM‐1 kinaseprotein kinasesSR protein kinase 1

Identifiers

PMID39462863
PMCPMC11809128

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.